The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable.
Chin-Lenn L, De Boer RH, Segelov E, Marx GM, Hughes TM, McCarthy NJ, White SC, Foo SS, Rutovitz JJ, Della-Fiorentina S, Jennens R, Antill YC, Tsoi D, Cronk MF, Lombard JM, Kiely BE, Chirgwin JH, Gorelik A, Mann GB.
Chin-Lenn L, et al.
Asia Pac J Clin Oncol. 2018 Dec;14(6):410-416. doi: 10.1111/ajco.13075. Epub 2018 Sep 30.
Asia Pac J Clin Oncol. 2018.
PMID: 30270527